slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 44,011-44,040
Pages 10,126
Rows per page 30
Component
44,011-44,040 of 303,780
63
The slide illustrates the mechanism of action for two therapeutic modalities derived from the same TCR discovery platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 2 hits
64
The slide uses a comparative framework to explain the safety profile of their technology platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 2 hits
65
The slide uses a flywheel-style circular diagram to represent the iterative nature of the data platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 2 hits
66
The slide highlights the breadth of the company's intellectual property protection across major global regions.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 2 hits
72
Includes waterfall plot and spider plot (change in tumor size over time).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 2 hits
74
Data cut-off Sep 30, 2023. N=28 patients.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 2 hits
01
Includes date and ticker symbol.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations 2 hits
06
Includes a biological process diagram showing B-cell development and target markers (CD19, CD20, BCMA).Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle2 hits
16
Includes comparative bar charts for transduction efficiency and toxicity markers, and flow cytometry data for anti-exhaustion.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle2 hits
19
The slide uses a causal chain framework to link cellular pathology to systemic organ damage.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle2 hits
23
Includes FDA approval precedents as a footnote to justify the clinical strategy.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle2 hits
38
The slide uses a step-wise diagram to illustrate dose escalation in a clinical trial setting.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle2 hits
57
The slide uses a process-flow style layout to connect platform capabilities to specific product outcomes.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle2 hits
59
The slide uses a process-like flow from the 3 pillars to the specific product outcomes.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle2 hits
60
Includes date and ticker symbol.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle2 hits
07
The slide uses a structural diagram to highlight the substitution of the 'Tumor Binding Domain' with the 'COBRA Binder' in the NXC-201 molecule.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Logic Chain2 hits
15
Includes comparative data charts for transduction efficiency and signaling, and flow cytometry data for anti-exhaustion.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire2 hits
18
The slide uses a causal chain to link cellular pathology to systemic organ damage.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action2 hits
21
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath2 hits
22
Includes a footnote citing FDA approval precedents for similar single-arm studies.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath2 hits
37
The diagram illustrates a dose-escalation process leading to the RP2D.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action2 hits
01
Includes date and ticker symbol.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 2 hits
06
Uses a human anatomy diagram to map therapeutic areas to diseases; includes a pyramid at the bottom highlighting 'Other diseases' and the key differentiator 'Overcoming neurotoxicity'.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution2 hits
16
Includes comparative data points for transduction efficiency and experimental data for signaling and exhaustion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 2 hits
19
The slide uses a causal chain framework to link cellular pathology to systemic organ damage.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction2 hits
23
Includes FDA approval precedents as a footnote to justify the clinical strategy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Roadmap2 hits
38
The slide uses a step-wise diagram to illustrate dose escalation in a clinical trial setting.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 2 hits
40
Includes scientific diagrams of molecular pathways, penetration depth charts, and efficacy metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 2 hits
50
The slide uses a process-flow style layout to connect the platform's core capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 2 hits
51
The slide uses a '3 Pillars' framework to explain the platform foundation, followed by a product-specific breakdown.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 2 hits